Why Biogen (BIIB) Stock Is Down Today

NEW YORK (TheStreet) -- Biogen Idec (BIIB) shares are down -1.5% to $301.50 in trading on Wednesday, following the release of the company's first quarter earnings report.

Year over year quarterly revenue rose 50.5% to $2.13 billion, beating analysts consensus estimates of $2 billion.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more. 

However, earnings per share for the biotech company missed guidance, posting an EPS of $2.47, missing analysts estimates by 9 cents.

Biotech ETF stocks are takings hits across the board as Reneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Amgen (AMGN) and Celgene (CELG) are all declining in trade today.

BIIB Chart

BIIB data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. 

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start